Stocks and Investing Stocks and Investing
Wed, February 7, 2024
Tue, February 6, 2024

Brian Abrahams Maintained (VRTX) at Hold with Increased Target to $420 on, Feb 6th, 2024


Published on 2024-10-28 08:47:07 - WOPRAI, Brian Abrahams
  Print publication without navigation


Brian Abrahams of RBC Capital, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold with Increased Target from $397 to $420 on, Feb 6th, 2024.

Brian has made no other calls on VRTX in the last 4 months.



There are 9 other peers that have a rating on VRTX. Out of the 9 peers that are also analyzing VRTX, 4 agree with Brian's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • William Pickering of "Bernstein" Downgraded from Buy to Hold on, Friday, February 2nd, 2024
  • Naz Rahman of "Maxim Group" Downgraded from Strong Buy to Hold on, Wednesday, January 31st, 2024
  • Paul Matteis of "Stifel" Reiterated at Hold and Held Target at $373 on, Wednesday, November 22nd, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $364 on, Wednesday, November 8th, 2023


These are the ratings of the 5 analyists that currently disagree with Brian


  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $508 on, Wednesday, January 31st, 2024
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $559 on, Wednesday, January 31st, 2024
  • Whitney Ijem of "Canaccord Genuity" Downgraded from Hold to Strong Sell and Increased Target to $379 on, Wednesday, January 24th, 2024
  • Evan Seigerman of "BMO Capital" Maintained at Buy with Increased Target to $415 on, Tuesday, November 7th, 2023
  • Eric Schmidt of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $370 on, Tuesday, October 17th, 2023
Contributing Sources